SCHEMBL10177266

SCHEMBL10177266

FC(F)(F)c1c[nH]c(-c2ccc(Br)nc2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.40
TRPV4 Q9HBA0 1/20 0.35
TRPV1 Q8NER1 1/20 0.35
KDM4E B2RXH2 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA3 P34903 1/20 0.33
HPGD P15428 1/20 0.33
IDO1 P14902 1/20 0.33
CYP19A1 P11511 1/20 0.33
PIK3CD O00329 1/20 0.32
PIK3CA P42336 1/20 0.32
PIK3CB P42338 1/20 0.32
PI4KA P42356 1/20 0.32
PIK3CG P48736 1/20 0.32
PI4KB Q9UBF8 1/20 0.32
TRPV3 Q8NET8 2/20 0.30
CLK1 P49759 2/20 0.30
CDK5 Q00535 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30442899 1.00 DGAT1 (0.40) DGAT1TRPV4TRPV1KDM4EGABRA1
SCHEMBL11623789 0.84 HPGD (0.43) DGAT1TRPV4KDM4EHPGD
SCHEMBL25196918 0.83 CYP2A6 (0.38) TRPV4HPGDIDO1PIK3CDPIK3CA
SCHEMBL16661274 0.83 KDM4E (0.45) DGAT1TRPV1KDM4EHPGD
SCHEMBL29429388 0.82 NPC1 (0.44) TRPV4KDM4EPIK3CD
SCHEMBL10177816 0.82 NPC1 (0.44) TRPV4PIK3CDPIK3CAPIK3CBPI4KA
SCHEMBL22166069 0.82 TRPV4 (0.34) TRPV4KDM4EHPGDIDO1PIK3CD
SCHEMBL22165974 0.82 NPC1 (0.44) TRPV4KDM4EPIK3CD
SCHEMBL8797359 0.77 GFER (0.50) DGAT1TRPV1KDM4EHPGD
SCHEMBL26093883 0.77 KDM4E (0.44) TRPV1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739397-A1 FUSED PYRAZOLE DERIVATIVES AS USP1 INHIBITORS Exelixis, Inc. (US) 2026-05-13 EP disclosed
US-12570634-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2026-03-10 US disclosed
US-20250026754-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LTD (CN) 2025-01-23 US disclosed
WO-2025010245-A1 FUSED PYRAZOLE DERIVATIVES AS USP1 INHIBITORS EXELIXIS, INC. (US) 2025-01-09 WO disclosed
US-20240190839-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2024-06-13 US disclosed
US-11739077-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2023-08-29 US disclosed
US-11739077-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2023-08-29 US disclosed
US-11739077-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof INSILICO MEDICINE IP LIMITED (HK) 2023-08-29 US disclosed
WO-2023148643-A1 FUSED BICYCLIC HETEROCYCLYL COMPOUNDS AS USP1 INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-08-10 WO disclosed
US-20230183210-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (HK) 2023-06-15 US disclosed
WO-2023083286-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF INSILICO MEDICINE IP LIMITED (CN) 2023-05-19 WO disclosed
EP-2862856-B1 IMIDAZOLE AND TRIAZOLE COMPOUNDS AS DGAT-1 INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2018-08-01 EP disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 US disclosed
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-02-23 US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 US disclosed
US-9546155-B2 Aromatic heterocyclic compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2017-01-17 US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 US disclosed
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-11 US disclosed
EP-2862856-A1 AROMATIC HETEROCYCLIC COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2015-04-22 EP disclosed
WO-2012081736-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158844-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DGAT1 1688/4885TRPV4 2374/4885TRPV1 1867/4885
US-20250026754-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 DGAT1 3252/4885TRPV4 4879/4885TRPV1 4850/4885
US-20230183210-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 DGAT1 3016/4885TRPV4 4879/4885TRPV1 4863/4885
US-20240190839-A1 SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF USP1, USP2, USP28 DGAT1 3016/4885TRPV4 4879/4885TRPV1 4863/4885
US-20170050950-A1 AROMATIC HETEROCYCLIC COMPOUND GPR119, NR0B1, BET1 DGAT1 1688/4885TRPV4 2374/4885TRPV1 1867/4885
US-11739077-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof USP1, USP2, USP28 DGAT1 3016/4885TRPV4 4879/4885TRPV1 4863/4885
US-12570634-B2 Small molecule inhibitors of ubiquitin specific protease 1 (USP1) and uses thereof USP1, USP2, USP3 DGAT1 4504/4885TRPV4 4796/4885TRPV1 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.